FDA Highlights Programs for Innovators at ACR DSI Summit
The FDA joined the ACR®️ Data Science Summit June 9 to give an update about its Total Product Life Cycle Advisory Program.
Read moreACR® is developing comments in response to a U.S. Department of Health and Human Services (HHS) Request for Information (RFI) that seeks input on topics including clinical AI regulation, reimbursement, and research and development to advance AI used in patient care.
Specifically, HHS is interested in learning about how these areas of federal influence can be leveraged to encourage clinical AI adoption and use, foster public trust and confidence, improve policy clarity, and align federal incentives. The RFI features a series of broad discussions followed by targeted questions for stakeholders' consideration.
If you have questions or would like to provide input to be considered for ACR’s response to the RFI, contact Michael Peters, Senior Director, Government Affairs, Lindsay Robbins, Regulatory Policy Specialist, or Christina Berry, Team Lead, Economic Policy.
FDA Highlights Programs for Innovators at ACR DSI Summit
The FDA joined the ACR®️ Data Science Summit June 9 to give an update about its Total Product Life Cycle Advisory Program.
Read moreLower Fee Now in Effect to File No Surprises Act Disputes
Federal agencies released a final rule that updates the No Surprises Act independent dispute resolution process. The rule lowers the IDR administrative or filing fee from $115 to $15.
Read moreACR Urges Funding for NIH All of Us Program
ACR urges Congress to provide dedicated funding for NIH’s All of Us Research Program, a leader in precision medicine technologies and a valuable tool for researchers.
Read more